Methylation of the GATA4 gene in urine samples as a marker for bladder cancer detection
View Patent ↗A method of detecting a predisposition to, or the incidence of, bladder cancer in a sample comprises detecting an epigenetic change in at least one gene selected from FOXE1 and GATA4. Detection of the epigenetic change is indicative of a predisposition to, or the incidence of, bladder cancer. The sample comprises nucleic acid molecules from bladder cells. The methods may be used to select treatments and patients for treatment. Related kits include primers allowing the methylation status of the genes to be determined.
1. A method comprising:
(a) treating genomic DNA from bladder cells in a urine sample with a reagent which selectively modifies unmethylated cytosine residues in the genomic DNA to produce modified residues but which does not modify methylated cytosine residues;
(b) amplifying the treated genomic DNA with primers comprising SEQ ID NO: 11 and SEQ ID NO: 12 to determine the methylation status of the GATA4 gene; and
(c) detecting hypermethylation of the GATA4 gene.
2. The method of claim 1 which comprises determining the methylation status of a panel of genes comprising the GATA4 gene together with one, two, three, four or five additional genes, and detecting methylation in at least one of the additional genes in the panel.
3. The method of claim 2 wherein the additional genes are selected from TWIST1, NID2 and CCNA1.
4. The method of claim 2 wherein the panel of genes comprises, consists essentially of or consists of a panel of genes selected from FOXE1 and TWIST1; FOXE1, TWIST1 and NID2; FOXE1, CCNA2 and NID2; GATA4 and NID2; GATA4, NID2 and TWIST1; CCNA1, NID2 and GATA4 or FOXE1 and GATA4.
5. The method of claim 1 wherein a stabilising buffer is added to the urine sample once collected, thus permitting the sample to be stored for a period of up to 72 hours at room temperature without the need for centrifugation of the sample.
6. The method of claim 1 which utilises a probe comprising the nucleotide sequences of SEQ ID NO: 10 (GATA4) in order to determine the methylation status.
7. A method comprising:
(a) isolating genomic DNA from a urine sample comprising bladder cells and treating the genomic DNA with a reagent which selectively modifies unmethylated cytosine residues in the genomic DNA to produce modified residues but which does not modify methylated cytosine residues;
(b) amplifying the treated genomic DNA with primers comprising SEQ ID NO: 11 and SEQ ID NO: 12 to determine the methylation status of the GATA4 gene; and
(c) detecting hypermethylation of the GATA4 gene.
8. The method of claim 7 which comprises determining the methylation status of a panel of genes comprising the GATA4 gene together with one, two, three, four or five additional genes, and detecting methylation in at least one of the additional genes in the panel.
9. The method of claim 8 wherein the additional genes are selected from TWIST1, NID2 and CCNA1.
10. The method of claim 8 wherein the panel of genes comprises, consists essentially of or consists of a panel of genes selected from FOXE1 and TWIST1; FOXE1, TWIST1 and NID2; FOXE1, CCNA2 and NID2; GATA4 and NID2; GATA4, NID2 and TWIST1; CCNA1, NID2 and GATA4 or FOXE1 and GATA4.
11. The method of claim 7 wherein a stabilising buffer is added to the urine sample once collected, thus permitting the sample to be stored for a period of up to 72 hours at room temperature without the need for centrifugation of the sample.
12. The method of claim 7 which utilises a probe comprising the nucleotide sequences of SEQ ID NO: 10 (GATA4) in order to determine the methylation status.